Edition:
United Kingdom

Synergy Pharmaceuticals Inc (SGYP.OQ)

SGYP.OQ on NASDAQ Stock Exchange Global Select Market

1.80USD
15 Jun 2018
Change (% chg)

$-0.01 (-0.55%)
Prev Close
$1.81
Open
$1.80
Day's High
$1.82
Day's Low
$1.78
Volume
9,551,854
Avg. Vol
986,173
52-wk High
$4.83
52-wk Low
$1.42

Latest Key Developments (Source: Significant Developments)

CVI Investments reports a 7.9 pct passive stake in Synergy Pharmaceuticals as of Nov 13, 2017
Wednesday, 22 Nov 2017 

Nov 22 (Reuters) - Synergy Pharmaceuticals Inc :CVI Investments Inc reports a 7.9 percent passive stake in Synergy Pharmaceuticals Inc as of November 13, 2017 - SEC Filing‍​.  Full Article

Synergy Pharma announces pricing of offering of common stock and warrants
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals announces pricing of offering of common stock and warrants.Synergy Pharmaceuticals - ‍pricing of offering of 21.7 million shares with accompanying warrants at combined price to public of $2.58/share and warrant​.  Full Article

Synergy Pharmaceuticals posts Q3 loss per share $0.22
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Synergy Pharmaceuticals Inc :Synergy Pharmaceuticals reports third quarter 2017 financial results and business update.Q3 loss per share $0.22.Q3 sales $5.0 million versus I/B/E/S view $4.5 million.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Synergy Pharmaceuticals Inc - ‍cash and cash equivalents were about $117.8 million at end of quarter​.  Full Article

Synergy Pharma's bowel drug succeeds in first phase 3 trial
Friday, 9 Dec 2016 

Synergy Pharmaceuticals Inc : Synergy Pharmaceuticals announces positive results in first phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C) . Synergy Pharmaceuticals Inc - preliminary analysis of data indicates that both plecanatide 3 mg and 6 mg doses met study's primary endpoint . Synergy Pharmaceuticals -pending approval in CIC indication, co plans to file new drug application supplement with clinical data for plecanatide in IBS-C in q1 2017 . Synergy Pharmaceuticals Inc - four patients in trial (0.4%) experienced serious adverse events . Synergy Pharma- common adverse event was diarrhea that was in 3.2% of patients in 3 mg,3.7% patients in 6 mg dose groups versus 1.3% placebo-treated patients .Synergy Pharmaceuticals announces positive results in first phase 3 trial of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C).  Full Article

Synergy Pharma Q2 net loss $38.6 million
Monday, 8 Aug 2016 

Synergy Pharmaceuticals Inc : Synergy pharmaceuticals reports second quarter 2016 financial results and business update .Net loss in q2 of 2016 was $38.6 million, as compared to a net loss of $33.7 million incurred in q2 of 2015.  Full Article

Synergy Pharma updates on FDA review clinical development program
Friday, 15 Jul 2016 

Synergy Pharmaceuticals Inc : Provides update on ongoing FDA review Of Plecanatide CIC NDA and IBS-C clinical development program . Provides update on ongoing FDA review of Plecanatide CIC NDA and IBS-C clinical development program . Company has decided to continue patient enrollment for its two ongoing phase 3 clinical trials with Plecanatide in IBS-C .Intend to file Plecanatide NDA in IBS-Cin Q1 of 2017.  Full Article

BRIEF-Paulson & Co Ups Share Stake In Viacom, Dish, Cuts In Caesars Entertainment

* PAULSON & CO UPS SHARE STAKE IN VIACOM TO 2.6 MILLION CLASS B SHARES FROM 1 MILLION CLASS B SHARES - SEC FILING